Immatics N.V.
No SEC Form 4 filings for $IMTX in the last 30 days.
See all $IMTX insider activity →Immatics N.V. (NASDAQ: IMTX) reported Q2 2026 results and a SUPRAME Phase 3 update for anzu-cel (IMA203) in advanced melanoma. PFS events are occurring more slowly than modeled, so the company will use a single streamlined final PFS analysis and add ~90 patients to strengthen OS. SUPRAME final PFS topline is expected H1 2027, with BLA submission in 2027. Cash: $448.2M as of June 30, 2026.
Baker Bros. Advisors LP and related reporting persons filed Amendment No. 6 reporting beneficial ownership of 9,508,565 ordinary shares of Immatics N.V. (IMTX), held via Baker Brothers Life Sciences, L.P. and 667, L.P. The stake equals 7.0% based on 136,673,161 shares outstanding as of March 31, 2026, per Immatics’ Form 6-K.
The article provides financial information for Immatics N.V. (MUN:4A3), specifically focusing on its operating cash flow per share. It presents the value, change, and percentage change for a given period, allowing investors to quickly assess this key financial metric.
Over the past 7 days, alphai's AI scored 2 news stories mentioning IMTX (Immatics N.V.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent IMTX coverage spans financial news and technology.
Protocol amendment and updated event dynamics change the statistical path to PFS topline and potentially de-risk the FDA-facing regulatory strategy.
The filing is a new disclosed ownership stake that can affect perceived control and potential future activism or liquidity expectations, but it is not an operational catalyst.
The reported operating cash flow per share for Immatics N.V. indicates a stable or slightly improved liquidity position, which could be positive for the company's valuation.
The upgrade of Immatics (NASDAQ:IMTX) from 'sell' to 'hold' by Wall Street Zen suggests a cautiously optimistic outlook, supported by increased institutional interest. This may lead to a moderate positive price movement in the near term.
Immatics (IMTX) reported a Q3 loss and missed revenue estimates, indicating potential short-term weakness. The stock's recent performance may be affected, but the fundamental outlook remains uncertain due to broader industry factors.
alphai scores every news story that mentions IMTX with an AI model for sentiment and relevance, and aggregates insider trades from Immatics N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Immatics N.V. (NASDAQ: IMTX) reported Q2 2026 results and a SUPRAME Phase 3 update for anzu-cel (IMA203) in advanced melanoma. PFS events are occurring more slowly than modeled, so the company will use a single streamlined final PFS analysis and add ~90 patients to strengthen OS. SUPRAME final PFS topline is expected H1 2027, with BLA submission in 2027. Cash: $448.2M as of June 30, 2026.
6 min readBaker Bros. Advisors LP and related reporting persons filed Amendment No. 6 reporting beneficial ownership of 9,508,565 ordinary shares of Immatics N.V. (IMTX), held via Baker Brothers Life Sciences, L.P. and 667, L.P. The stake equals 7.0% based on 136,673,161 shares outstanding as of March 31, 2026, per Immatics’ Form 6-K.
2 min readThe article provides financial information for Immatics N.V. (MUN:4A3), specifically focusing on its operating cash flow per share. It presents the value, change, and percentage change for a given period, allowing investors to quickly assess this key financial metric.
2 min readWall Street Zen upgraded Immatics (NASDAQ:IMTX) from a "sell" to a "hold" rating. This upgrade aligns with a broader analyst consensus of "Moderate Buy" for the clinical-stage biotechnology company, which focuses on T cell receptor (TCR)-based immunotherapies for solid tumors. Institutional investors, including T. Rowe Price and Baker Bros., have significantly increased their stakes in Immatics, which currently trades with a market cap of $1.22 billion.
2 min readImmatics (IMTX) delivered earnings and revenue surprises of +2.00% and -50.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readThe mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 min readStafford, Texas and Tuebingen, Germany, May 31, 2025 - Immatics N.V. ( NASDAQ: IMTX, "Immatics" or the "Company" ) , a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data ...
3 min read
